Lv21
156 积分 2021-09-17 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
5小时前
已完结
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
5天前
已完结
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
23天前
已完结
Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL
23天前
已完结
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
24天前
已完结
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
25天前
已完结
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
25天前
已关闭
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
25天前
已关闭
Comparing Symptom Response Among Antipsychotic Medications in CATIE
26天前
已关闭
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
1个月前
已完结
皖公网安备34019202002308
